Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 3
1973 9
1974 4
1975 21
1976 16
1977 15
1978 15
1979 18
1980 14
1981 14
1982 4
1983 15
1984 9
1985 17
1986 6
1987 19
1988 12
1989 21
1990 26
1991 21
1992 26
1993 27
1994 31
1995 49
1996 43
1997 54
1998 47
1999 52
2000 53
2001 66
2002 71
2003 66
2004 71
2005 77
2006 78
2007 80
2008 75
2009 76
2010 77
2011 74
2012 95
2013 117
2014 122
2015 147
2016 131
2017 125
2018 130
2019 150
2020 142
2021 143
2022 95
2023 93
2024 43

Text availability

Article attribute

Article type

Publication date

Search Results

2,692 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hodgkin Lymphoma by Clinical Course"
Page 1
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Mayo Clin Proc. 2015. PMID: 26541251 Review.
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within the subcategorization o …
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...Patients with early-stage disease are typically treated …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually …
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044. Blood. 2020. PMID: 32877522 Free article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. ...The clinical course of NLPHL is indolent in the majority of cases. Most patients present with earl …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clini …
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2020 Aug;95(8):978-989. doi: 10.1002/ajh.25856. Epub 2020 Jun 8. Am J Hematol. 2020. PMID: 32384177 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States. DIAGNOSIS: Hodgkin lymphoma is composed of two disti …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has traditionally been recognized as having two morphologic patterns, nodular and diffuse, and the current WHO definition of NLPHL requires at least a partial nodular pattern. ...Prominent sclerosis was identif …
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has traditionally been recognized as having two morphologic patterns, …
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A. Fuchs M, et al. J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10. J Clin Oncol. 2019. PMID: 31498753 Clinical Trial.
PURPOSE: Combined-modality treatment (CMT) with 2 ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been c …
PURPOSE: Combined-modality treatment (CMT) with 2 ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy i …
Hodgkin lymphoma.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hoppe RT, et al. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. doi: 10.6004/jnccn.2011.0086. J Natl Compr Canc Netw. 2011. PMID: 21917626 No abstract available.
Treatment of Richter's Syndrome.
Condoluci A, Rossi D. Condoluci A, et al. Curr Treat Options Oncol. 2017 Nov 21;18(12):75. doi: 10.1007/s11864-017-0512-y. Curr Treat Options Oncol. 2017. PMID: 29159711 Review.
Early recognition of chronic lymphocytic leukemia (CLL) patients presenting clinical features suspected for a transformation is useful to avoid exposing them to multiple lines of therapy that, being targeted to CLL progression, have poor efficacy against RS. ...If t …
Early recognition of chronic lymphocytic leukemia (CLL) patients presenting clinical features suspected for a transformation is usefu …
Biology and treatment of Richter syndrome.
Rossi D, Spina V, Gaidano G. Rossi D, et al. Blood. 2018 Jun 21;131(25):2761-2772. doi: 10.1182/blood-2018-01-791376. Epub 2018 Apr 24. Blood. 2018. PMID: 29692342 Free article. Review.
Richter syndrome (RS) is the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Two pathologic variants of RS are recognized: namely, the diffuse large B-cell lymphoma (DLBCL) variant and the rare Hodgkin lymphoma …
Richter syndrome (RS) is the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Two pathologi …
Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML. Goel A, et al. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):261-70. doi: 10.1016/j.clml.2014.01.006. Epub 2014 Feb 3. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24650975 Review.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of classical Hodgkin lymphoma. It is characterized histologically by presence of lymphohistiocytic cells which have B-cell phenotype, are positive for CD19, CD20, CD45, CD79 …
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of classical Hodgkin lymphoma. It …
2,692 results